CX-801

DEVELOPMENT STEP phase-1
SPONSOR MATRIX CytomX Therapeutics [CTMX]
MECHANISM TARGET // UNMAPPED_TARGET

[THERAPEUTIC_PROFILE]

Target Indications

Advanced Melanoma

Mechanism Abstract

CX-801 is a wholly-owned interferon (IFN) alpha-2b Probody® therapeutic. Interferons are approved anti-cancer therapies but are limited by narrow therapeutic windows. Based on preclinical studies, CX-801 demonstrated a wide therapeutic index with an enhanced tolerability profile versus unmasked IFN, without compromising its potent antitumor effects.

[CLINICAL_TRIALS_REGISTRY]

TOTAL EXTRACTED1
RECRUITING STATUS1
COMPLETED RUNS0
REGISTRY & PHASE
TESTED CONDITION
STUDY TITLE & LIFECYCLE TIMELINES
STATUS
➔
P-1NCT06462794
Solid Tumor, Adult
N=121Est. Finish: 2029-06-30
First In Human Study of CX-801 in Advanced Solid Tumors
recruiting